Drug Profile
Research programme: respiratory disorder therapeutics - PARI Pharma
Alternative Names: Disodium Cromoglycate - PARI; DSCG - PARI Pharma; Levofloxacin VibrENT; Sodium cromoglicate - PARI PharmaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PARI Pharma GmbH
- Class Benzopyrans; Chromones; Fluoroquinolones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; Mast cell stabilisers; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Rhinosinusitis
Highest Development Phases
- No development reported Rhinosinusitis
- Discontinued Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rhinosinusitis in Germany (Inhalation)
- 11 Sep 2013 Research programme: respiratory disorder therapeutics - PARI Pharma is available for licensing as of 11 Sep 2013.
- 26 Jan 2010 Preclinical trials in Asthma in Germany (Inhalation)